HTBX - HTBX STOCK NEWS

Heat Biologics, (NASDAQ: HTBX), a clinical-stage biopharmaceutical company, announced a conference call on September 2nd at 11:00 AM ET, hosted by CEO Jeff Wolf. The call aims to provide updates on the company's activities and can be accessed via phone or webcast. Heat Biologics is focused on developing therapies to modulate the immune system, utilizing its gp96 platform. The company has multiple products in development, including HS-110, which has completed enrollment in a Phase 2 trial, and several programs in preclinical and early clinical stages.

Heat Biologics, Inc. (NASDAQ: HTBX) has announced the launch of its new subsidiary, Skunkworx Bio, Inc., aimed at transforming drug discovery through a unique platform. Utilizing proprietary libraries of 'Pocket Biologics,' Skunkworx intends to accelerate drug development by pinpointing druggable targets with advanced computational methods. The approach has already yielded promising preclinical assets. CEO Jeff Wolf noted that this innovation integrates discovery, development, and manufacturing to expedite the path to clinic-ready therapies, enhancing their portfolio across various therapeutic indications.

Heat Biologics (NASDAQ: HTBX) announced the appointment of former U.S. Senator Mark Pryor to its Biothreat Advisory Board. Pryor brings extensive experience in policy and government affairs, having served on key Senate committees, including Armed Services and Homeland Security. CEO Jeff Wolf expressed that Pryor's expertise will be crucial in advancing the company’s biothreat initiatives. Heat Biologics focuses on developing innovative therapies to modulate the immune system, with several product candidates in different clinical trials.

Heat Biologics (NASDAQ: HTBX) has announced the formation of a Biothreat Advisory Board, welcoming Andrew C. Weber and Dr. Gregory Koblentz. Weber, a former Assistant Secretary of Defense, brings expertise in nuclear, chemical, and biological defense, while Koblentz is a leading academic in the field. CEO Jeff Wolf expressed optimism about their insights enhancing the company's biodefense initiatives. Heat Biologics is focused on developing therapies that modulate the immune system, with several candidates in clinical trials.

Heat Biologics (NASDAQ: HTBX) has initiated a new biosecurity/biodefense initiative following its research from the COVID-19 pandemic. The company has formed an advisory board with two significant additions: David Lasseter, former Deputy Assistant Secretary of Defense for Countering Weapons of Mass Destruction, and Jack Kingston, a former US Representative. Their expertise will support the aim of developing timely response solutions to current and future biological threats. The initiative aims to enhance national security and improve health response mechanisms.

Heat Biologics, Inc. (NASDAQ: HTBX) reported significant clinical and operational milestones for Q2 2021. The company presented promising survival data for HS-110 in non-small cell lung cancer at the ASCO Annual Meeting and is exploring FDA pathways for Phase 3 registration. They are also expanding R&D facilities, improving in-house capabilities. Financially, Heat holds approximately $122.5 million in cash and short-term investments, although they reported a net loss of $6.5 million for the quarter, compared to $4.5 million the prior year.

Heat Biologics (NASDAQ: HTBX) announces a groundbreaking ceremony for its new biomanufacturing facility in San Antonio, supported by $1.0 million in tax abatements from local government. The facility will enhance the capabilities of its subsidiary, Scorpion Biological Services, enabling in-house development of immuno-assays, biomarker research, and cGMP manufacturing. CEO Jeff Wolf stated this move aims to reduce costs and development timelines while also providing support to other biopharma companies. The ceremony is streamed live as part of this significant expansion.

Heat Biologics, Inc. (Nasdaq: HTBX) announced its inclusion in the Russell Microcap® Index effective June 28, 2021, increasing its visibility to investors. This move follows the annual Russell indexes reconstitution based on market-capitalization rankings and style attributes.

CEO Jeff Wolf stated that this achievement reflects their progress in clinical programs, including oncology and COVID-19 vaccine development, supported by a strong balance sheet with over $132 million in cash and short-term investments as of Q1 2021.

Heat Biologics (NASDAQ: HTBX) announced plans to significantly expand its research and development facilities in Morrisville, North Carolina. This expansion aims to enhance in-house capabilities, including antibody synthesis and an improved vivarium for pre-clinical studies. CEO Jeff Wolf stated that this move is expected to accelerate R&D timelines and reduce costs associated with third-party services. The company continues to develop therapies targeting cancer and infectious diseases, including a COVID-19 vaccine.